Jin Wu Financial News | According to Symphony Health data, sales of Hewang Pharmaceutical (00013) fruquintinib in US medical institutions (including US hospitals, doctors' clinics, long-term medical institutions, etc.) have increased month-on-month since launch 2023.11-2024.03 to reach 1.44/5.18/10.31/13.30/15.33 million US dollars, respectively (258%/99%/29%/15% month-on-month increase): Miquintinib is accelerating in the US, in the future, along with Europe and The Japanese market has been approved. The bank expects the company to obtain a certain milestone amount, and the peak global sales of furoquintinib is expected to exceed 500 million US dollars.
The bank said that after fruquintinib was approved in the US in 2023.11, Takeda disclosed its 2023 financial report. As of 2024.03.31, fuquintinib had achieved sales of about 6,700 cubic US dollars in the US. Excluding 15.1 million US dollars in 202304, furoquintinib achieved sales volume of about 52 million US dollars in 2024Q1. The commercial volume exceeded expectations. According to Takeda's financial guidance, it is expected that in fiscal year 2024 (2023.04.012025.0331, furoquintinib will achieve a sales growth rate of more than 100%. As Europe and Japan receive further approval, global commercialization is expected to accelerate. The bank is optimistic that furoquintinib will further open up overseas markets and maintain an “gain” rating.